IL6 and systemic sclerosis: In the early stages of SSc, IL-6 leads to damage-associated molecular patterns that maintain inflammation and play an important role in fibroblast transformation development, and the use of tocilizumab can inhibit IL-6 by binding to IL-6R, thus inhibiting inflammation and fibrosis (168).